1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Late Stage Chronic Kidney Disease Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Late Stage Chronic Kidney Disease Drugs Market Regional Analysis
6.2 Europe Late Stage Chronic Kidney Disease Drugs Market Revenue 2017-2027 (US$ Million)
6.3 Europe Late Stage Chronic Kidney Disease Drugs Market Forecast Analysis
7. Europe Late Stage Chronic Kidney Disease Drugs Market Analysis – by Product Type
7.1 Calcimimetics
- 7.1.1 Overview
- 7.1.2 Calcimimetics: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Vitamin D
- 7.2.1 Overview
- 7.2.2 Vitamin D: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.3 Sterols
- 7.3.1 Overview
- 7.3.2 Sterols: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.4 Potassium Binders
- 7.4.1 Overview
- 7.4.2 Potassium Binders: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.5 Calcium-Based Phosphate Binders
- 7.5.1 Overview
- 7.5.2 Calcium-Based Phosphate Binders: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Europe Late Stage Chronic Kidney Disease Drugs Market Analysis – by Indication
8.1 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- 8.1.1 Overview
- 8.1.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- 8.2.1 Overview
- 8.2.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Late Stage Chronic Kidney Disease Induced Hyperkalaemia
- 8.3.1 Overview
- 8.3.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. Europe Late Stage Chronic Kidney Disease Drugs Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Online Pharmacies
- 9.2.1 Overview
- 9.2.2 Online Pharmacies: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. Europe Late Stage Chronic Kidney Disease Drugs Market – Europe Analysis
10.1 Overview
10.2 Europe
- 10.2.1 Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.2.1.1 Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 UK:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 UK: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.1.2 UK: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.1.3 UK: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.2.1.2 Germany:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Germany: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.2.2 Germany: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.2.3 Germany: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.2.1.3 France:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 France: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.3.2 France: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.3.3 France: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.2.1.4 Russia:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.4.1 Russia: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.4.2 Russia: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.4.3 Russia: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.2.1.5 Italy:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.5.1 Italy: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.5.2 Italy: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.5.3 Italy: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.2.1.6 Rest of Europe:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.6.1 Rest of Europe: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.6.2 Rest of Europe: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.6.3 Rest of Europe: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 AbbVie Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Amgen
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 AstraZeneca
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sanofi
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Kyowa Kirin Co., Ltd
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Company Limited
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Astellas Pharma Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bayer AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Vifor Pharma Management Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Akebia Therapeutics, Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For Europe Late Stage Chronic Kidney Disease Drugs Market
